Fluvoxamine Shows Promise in Lightening Long COVID Fatigue

A recent trial in Brazil explored whether two familiar medicines could ease the persistent tiredness that follows a COVID infection. The study focused on fluvoxamine, an inexpensive antidepressant, and metformin, a common diabetes drug. Researchers randomly assigned nearly 400 adults—each with fatigue lasting three months or more—to receive either fluvoxamine, metformin, or a placebo for two months. The results favored the antidepressant: patients on fluvoxamine reported noticeably less exhaustion, with a 99‑percent confidence that the effect surpassed the placebo. In contrast, metformin offered no measurable relief, despite earlier hints it might reduce long COVID risk if taken during the initial illness.These findings give doctors a tangible option for patients who have longed for evidence‑based relief from the most crippling symptom of long COVID. The medication’s established safety profile and global availability could accelerate its adoption in clinical settings. However, the study stops short of identifying which patients benefit most or how fluvoxamine dampens fatigue. Future research should investigate dosage, timing, and underlying mechanisms to refine treatment guidelines. Overall, the trial marks a significant step toward practical solutions for long COVID fatigue, offering hope that an existing drug could be repurposed to improve quality of life for thousands still battling post‑viral exhaustion.